Navigation Links
Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
Date:1/22/2008

identifying and licensing clinically enabled compounds like rufinamide allows Synosia to quickly move into smart, efficient clinical trials designed to rapidly establish proof of concept in new therapeutic areas," said Synosia Chief Executive Officer and President Ian Massey. "Rufinamide, a structurally novel compound with proven efficacy in epilepsy and with an extensive safety database, was a perfect candidate to demonstrate the soundness of our strategy. The impressive speed in which this trial was designed, executed and completed is a real highlight for us."

About Rufinamide

The drug was originally discovered and developed by Novartis, which granted certain licensing rights to Eisai of Japan in 2004. In January 2007, Eisai received marketing authorisation in the European Union for Inovelon(R) (rufinamide) as adjunctive anti-epileptic therapy in Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy that develops in early childhood. Eisai has also submitted an NDA for rufinamide to the US Food and Drug Administration (FDA) for adjunctive therapy in adults and adolescents. The extensive clinical development program for rufinamide in epilepsy has generated over 2500 patient-years of exposure to the drug.

About Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialise innovative and clinically differentiated products for unmet medical needs in psychiatry and neurology. The privately-owned company is developing six clinical-stage compounds acquired through key partnerships with Novartis, Roche and Syngenta, including two marketed drugs that will be tested in new indications, extending their reach into new therapeutic areas with combined sales potential in excess of US$2.5 billion. Synosia has offices in Basel, Switzerland, and South San Francisco, CA.

Synosia Therapeutics has raised US$32.5 million funding from Versant Ventures (Menlo Park, CA), Abingworth Management (London), 5AM Ventures (Menlo Park, CA) a
'/>"/>

SOURCE Synosia Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Synosia Therapeutics Announces Appointment of Chief Business Officer
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Bellingham, Washington, USA (PRWEB) December 16, 2014 ... Kirstin Baum, manager at Philipps- Universität Marburg’s Department ... optics and photonics, in the newly released ... 2015-2016. “And never be too shy to ask ... STEM (science, technology, engineering, and mathematics) occupations ranging ...
(Date:12/17/2014)... December 17, 2014 This report ... Quartz Tubing industry. For an overview analysis, the ... application, industry chain structure, industry overview, policy analysis, ... tubing industry has witnessed rapid development with ... of acquisitions. This report mentions quartz tubing upstream ...
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014   Synageva ... biopharmaceutical company developing therapeutic products for rare disorders, announced ... Conference being held in San Francisco, CA. ... President and Chief Executive Officer, will present on Monday, ... EST).  The presentation will be webcast live and may ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 32020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
... GE Medical Systems , has signed a clinical ... of the National Cancer Institute (NCI) for multi-site clinical ... emission tomography (PET), applied to the management of patients ... used to image DNA synthesis, showing high contrast in ...
... complexities of the biotech industry to investors, academics and start-up biotech ... and expensive process. What they don't understand is why. , ... us the following pathway: , , , ,Logical questions to ... life of a drug is 20 years and it takes up ...
... by a Washington, DC, think tank slammed Wisconsins efforts ... in Madison could raise that score, according to the ... the Department of Administration (DOA) after the ... also said the Center for Economic Development (CFED) ...
Cached Biology Technology:GE Medical Systems Signs Clinical Trial with National Cancer Institute 2The Complexities, Cost of Midwest Biotech Drug Development 2The Complexities, Cost of Midwest Biotech Drug Development 3The Complexities, Cost of Midwest Biotech Drug Development 4Wisconsin to Get Serious about E-Government 2Wisconsin to Get Serious about E-Government 3Wisconsin to Get Serious about E-Government 4
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... is required to smoke "electronic cigarettes" marketed ... brands, with possible adverse effects on human health, ... The researchers used a smoking machine to ... with five e-cigarette brands. They examined the vacuum ...
... Troy, N.Y. Researchers have found that an enzyme ... unknown mechanism in providing the bacteria with energy. Because ... including humans, the finding offers insights into how drugs ... humans. Blanca Barquera, a Rensselaer associate professor ...
... --- Though much effort and many resources have been ... an international team of scientists shows that much suitable ... where the panda is reported to live. "This ... organizations develop comprehensive strategic plans for more effective conservation ...
Cached Biology News:Electronic cigarettes require more suction than conventional brands 2Electronic cigarettes require more suction than conventional brands 3Electronic cigarettes require more suction than conventional brands 4Rensselaer professor uncovers mysterious workings of cholera bacteria 2Rensselaer professor uncovers mysterious workings of cholera bacteria 3Most panda habitat is outside nature reserves according to joint MSU-Chinese research 2
Screening test for the detection of Salmonella sp. by means of DNA amplification, subsequent molecular hybridization and detection on a microtitre plate....
... three step procedure (PCR, Exonuclease III digestion ... one day. The typical cloning efficiency using ... Features and Benefits: , , Universal - ... expression vector , High Cloning Efficiency - ...
... or 384-well PCR plates Dimples on both sides ... plates End tabs on Thermo-Mat™ 384 fit into ... sealing is achieved with either Thermo-Mat™ 96 or 384 ... lid thermal cyclers Fully autoclavable May ...
... HistoMark Biotin Streptavidin-HRP Systems provide rapid, ... intracellular antigens in frozen or paraffin-embedded ... These systems also facilitate double or ... be performed simultaneously with primary antibodies ...
Biology Products: